News

A team led by Dr Sunny Kim from Florida International University looked at national US government databases covering visits to hospitals and family doctors. They found a large

The company has requested a meeting with the FDA to determine whether existing data are sufficient to respond to the agency’s concerns or whether additional studies will be

Shire resubmitted its application for the drug to the FDA with additional data after the regulator informed the company in December 2005 via an approvable letter that it

A large number of therapeutic drugs currently on the market involve G-protein coupled receptors (GPCR) in their mechanisms of action. However there is still great potential for further

AC-100, a novel synthetic peptide derived from an endogenous human protein produced by bone and dental cells, also demonstrated a favorable safety profile. Each year, more than 200

This study will take place in parallel to Mymetics’ ongoing preclinical trial in another primate model, recently initiated in collaboration with the Cochin Institute, Paris, France, the Institute

The expanded trial will now utilize an additional clinical trial site, the Montefiore Medical Center, New York, a leading cancer research center in the US “Montefiore Medical Center

The award is the second installation of a two-year, $2.9 million grant first announced in January 2005. The grant was awarded under the government’s biodefense initiative. The patch

Alnylam specializes in developing therapeutics based on RNAi, which is a naturally occurring mechanism within cells for selectively silencing and regulating specific genes. Since many diseases are caused